Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
10:39am, Thursday, 05'th Aug 2021
Insmed (INSM) delivered earnings and revenue surprises of -10.59% and 4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
07:30am, Thursday, 05'th Aug 2021
BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks
11:30am, Tuesday, 27'th Jul 2021
Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Insmed To Present at Two June Conferences
07:00am, Tuesday, 25'th May 2021
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseas
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
04:05pm, Wednesday, 19'th May 2021
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to
BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offerin
Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
01:54am, Tuesday, 11'th May 2021
BRIDGEWATER, N.J., May 11, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (t
INSM Stock: Over 15% Decrease Intraday Explanation
09:57am, Monday, 10'th May 2021
The stock price of Insmed Incorporated (NASDAQ: INSM) decreased by over 15% during intraday trading this morning. This is why it happened.
Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
07:00am, Monday, 10'th May 2021
BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500 million a
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript
11:15pm, Saturday, 08'th May 2021
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2021 Results - Earnings Call Transcript
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 07'th May 2021
BRIDGEWATER, N.J., May 7, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
07:30am, Thursday, 06'th May 2021
BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to
BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Incorporated (INSM) CEO Will Lewis on Q4 2020 Results - Earnings Call Transcript
02:21pm, Thursday, 25'th Feb 2021
Insmed Incorporated (INSM) CEO Will Lewis on Q4 2020 Results - Earnings Call Transcript
Insmed's Inhaled Treprostinil Palmitil Is Safe; Healthy Volunteers Study Show
08:37am, Friday, 19'th Feb 2021
Insmed Incorporated (NASDAQ: INSM) has announced topline results from the Phase 1 study evaluating treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The company plans to presen
